肾移植候选者评估和管理的KDIGO临床实践指南

2020-04-02 改善全球肾脏病预后组织 Transplantation . 2020 Apr;104(4S1 Suppl 1):S11-S103

2020年肾脏病:改善全球结果(KDIGO)关于评估和管理肾移植候选者的临床实践指南,旨在帮助世界各地的保健专业人员评估和管理潜在的死亡或活体捐赠肾移植候选者。本指南涉及一般候选者的问题,如移植的途径

中文标题:

肾移植候选者评估和管理的KDIGO临床实践指南

发布日期:

2020-04-02

简要介绍:

2020年肾脏病:改善全球结果(KDIGO)关于评估和管理肾移植候选者的临床实践指南,旨在帮助世界各地的保健专业人员评估和管理潜在的死亡或活体捐赠肾移植候选者。本指南涉及一般候选者的问题,如移植的途径、患者的人口统计学和健康状况因素,以及免疫学和社会心理评估。本指南还讨论了各种风险因素和合并症对个体移植适应性的作用,如依从性、吸烟、糖尿病、肥胖、围手术期问题、肾衰竭的原因、感染、恶性肿瘤、肺部疾病、心脏和外周动脉疾病、神经系统疾病、胃肠道和肝脏疾病、血液系统疾病、骨和矿物质疾病。本指南提供了对候选者个体方面的评估建议,以便分别考虑每个危险因素和合并症。目的是帮助临床团队吸收所有与个人相关的数据,在其当地的健康环境中进行考虑,并对移植的候选者进行整体判断。指南制定过程遵循推荐评估、发展和评价分级(GRADE)的方法。指南推荐主要基于对相关研究的系统回顾和我们对证据质量的评估,并提供推荐的优势。对证据的局限性进行了讨论,并指出了与以往指南的差异,还提供了未来研究的建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=KDIGO_Clinical_Practice_Guideline_on_the.9.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ebbef1c00199a271, title=肾移植候选者评估和管理的KDIGO临床实践指南, enTitle=, guiderFrom=Transplantation . 2020 Apr;104(4S1 Suppl 1):S11-S103, authorId=0, author=, summary=2020年肾脏病:改善全球结果(KDIGO)关于评估和管理肾移植候选者的临床实践指南,旨在帮助世界各地的保健专业人员评估和管理潜在的死亡或活体捐赠肾移植候选者。本指南涉及一般候选者的问题,如移植的途径, cover=, journalId=0, articlesId=null, associationId=108, associationName=改善全球肾脏病预后组织, associationIntro=改善全球肾脏病预后组织(Kidney Disease: ImprovingGlobal Outcomes,KDIGO)是一个国际性的非营利性组织,旨在通过促进和协调世界范围内的大合作,整合已有的相关工作,制定出适用于慢性肾病患者的临床实践指南,并在世界不同地区加以推广,以改善全球肾病患者的预后。, copyright=0, guiderPublishedTime=Thu Apr 02 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p>2020年肾脏病:改善全球结果(KDIGO)关于评估和管理肾移植候选者的临床实践指南,旨在帮助世界各地的保健专业人员评估和管理潜在的死亡或活体捐赠肾移植候选者。本指南涉及一般候选者的问题,如移植的途径、患者的人口统计学和健康状况因素,以及免疫学和社会心理评估。本指南还讨论了各种风险因素和合并症对个体移植适应性的作用,如依从性、吸烟、糖尿病、肥胖、围手术期问题、肾衰竭的原因、感染、恶性肿瘤、肺部疾病、心脏和外周动脉疾病、神经系统疾病、胃肠道和肝脏疾病、血液系统疾病、骨和矿物质疾病。本指南提供了对候选者个体方面的评估建议,以便分别考虑每个危险因素和合并症。目的是帮助临床团队吸收所有与个人相关的数据,在其当地的健康环境中进行考虑,并对移植的候选者进行整体判断。指南制定过程遵循推荐评估、发展和评价分级(GRADE)的方法。指南推荐主要基于对相关研究的系统回顾和我们对证据质量的评估,并提供推荐的优势。对证据的局限性进行了讨论,并指出了与以往指南的差异,还提供了未来研究的建议。</p>, tagList=[TagDto(tagId=261, tagName=肾移植)], categoryList=[CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2377, appHits=106, showAppHits=0, pcHits=591, showPcHits=2271, likes=0, shares=4, comments=6, approvalStatus=1, publishedTime=Fri Oct 23 16:46:27 CST 2020, publishedTimeString=2020-04-02, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Fri Oct 23 16:13:23 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 01:58:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=KDIGO_Clinical_Practice_Guideline_on_the.9.pdf)])
KDIGO_Clinical_Practice_Guideline_on_the.9.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1199396, encodeId=4ff71199396d5, content=几分几分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3a6455137, createdName=ms2000001050457721, createdTime=Fri Mar 04 15:38:12 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073193, encodeId=da8610e319382, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6fa2267688, createdName=12199db1m36(暂无昵称), createdTime=Tue Nov 23 14:33:11 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950055, encodeId=9157950055dd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=ms9056046557664914, createdTime=Mon Mar 22 09:44:59 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917597, encodeId=7cd691e59714, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:28:36 CST 2021, time=2021-01-17, status=1, ipAttribution=)]
    2022-03-04 ms2000001050457721

    几分几分

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1199396, encodeId=4ff71199396d5, content=几分几分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3a6455137, createdName=ms2000001050457721, createdTime=Fri Mar 04 15:38:12 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073193, encodeId=da8610e319382, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6fa2267688, createdName=12199db1m36(暂无昵称), createdTime=Tue Nov 23 14:33:11 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950055, encodeId=9157950055dd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=ms9056046557664914, createdTime=Mon Mar 22 09:44:59 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917597, encodeId=7cd691e59714, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:28:36 CST 2021, time=2021-01-17, status=1, ipAttribution=)]
    2021-11-23 12199db1m36(暂无昵称)

    非常好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1199396, encodeId=4ff71199396d5, content=几分几分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3a6455137, createdName=ms2000001050457721, createdTime=Fri Mar 04 15:38:12 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073193, encodeId=da8610e319382, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6fa2267688, createdName=12199db1m36(暂无昵称), createdTime=Tue Nov 23 14:33:11 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950055, encodeId=9157950055dd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=ms9056046557664914, createdTime=Mon Mar 22 09:44:59 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917597, encodeId=7cd691e59714, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:28:36 CST 2021, time=2021-01-17, status=1, ipAttribution=)]
    2021-03-22 ms9056046557664914

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1199396, encodeId=4ff71199396d5, content=几分几分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3a6455137, createdName=ms2000001050457721, createdTime=Fri Mar 04 15:38:12 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073193, encodeId=da8610e319382, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6fa2267688, createdName=12199db1m36(暂无昵称), createdTime=Tue Nov 23 14:33:11 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950055, encodeId=9157950055dd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=ms9056046557664914, createdTime=Mon Mar 22 09:44:59 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917597, encodeId=7cd691e59714, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:28:36 CST 2021, time=2021-01-17, status=1, ipAttribution=)]